Smith & Nephew PLC

Smith & Nephew’s stock price has declined by 11.3% from its 52-week high of £1,245.26 to its current price of £1,103.50.

Smith & Nephew PLC has strengthened its leadership with a key appointment and is poised for growth in the healthcare sector, driven by increasing demand for advanced wound care products.

Smith & Nephew PLC has made significant strides in the UK market through a partnership with Standard Health, but faces competition from major players and cautious market sentiment.

Smith & Nephew PLC has partnered with Standard Health to develop the UK’s first Orthopaedic Ambulatory Surgery Centre, enhancing the company’s presence in the UK healthcare sector.

Smith & Nephew has unveiled a new medial stabilized insert for its LEGION Total Knee System, designed to enhance kinematics, stability and procedural versatility.

Smith & Nephew PLC has secured a 10-year, up to $75 million contract with the US Department of Defense to provide Negative Pressure Wound Therapy systems.

Smith & Nephew’s stock price surges as its innovative PICO devices prove effective and cost-efficient in treating C-section patients, driving the company’s upward trajectory.

Smith & Nephew has made significant advancements in joint care with its CARTIHEAL AGILI-C Cartilage Repair Implant and CORI Surgical System, offering patients more effective and minimally invasive treatment options.

Smith & Nephew PLC reports steady revenue growth in Q1 2025, driven by operational improvements and strategic product launches, with shares increasing 7% following the announcement.

Smith & Nephew has demonstrated a steady and resilient performance in a volatile market, with a stable stock price and relatively high valuation metrics.